Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The FDA outlines a path to market entry for products where a randomized trial is no ...

A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction ...

Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in ...

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen ...

We conducted an open-label, randomized trial in Spain and Italy to evaluate the effect of beta-blocker therapy, as compared with no beta-blocker therapy, in patients with acute myocardial infarction ...

In patients with refractory systemic lupus erythematosus, in vivo generation of CD19 CAR T cells by means of lipid nanoparticles led to B-cell depletion, reduced disease activity, and no major toxi ...

Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...

An 89-year-old woman with severe tricuspid regurgitation presented with fever and cough after a recent diagnosis of influenza. Prominent forehead venous pulsations (shown in a video) were noted on ...